[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"John Elfar\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":132},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,76,108],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":20,"briefSummary":22,"conditions":23,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100561920",false,"NCT06596434","4-Aminopyridine to Treat Skin Burns","Inclusion Criteria:\n\n* Injured (burned) adults with a maximum severity of second-degree burns.\n* Burns involving at least 6cm2 of skin area\n* Acute burns within 7 days of injury\n* Cognitive ability to evaluate burn healing, report sensory and motor deficit during examination.\n* Adults aged 18-80\n* Ability to give written informed consent.\n* Capable of safely coming in for follow up visits on all scheduled appointments.\n\nExclusion Criteria:\n\n* History of multiple sclerosis, stroke or any other diagnosed neurological disorder\n* History of hypersensitivity to AMPYRA® or 4-aminopyridine\n* Current use of aminopyridine medications, including other compounded 4-AP\n* Suspected renal impairment based on the Choyke questionnaire.\n* History of difficult compliance with timely follow up\n* Patients outside the age range\n* Unable to provide informed consent.\n* Patients with a known history of a seizure disorder (4-AP overdose can, in selected cases, result in limited seizure activity).\n* Patients with a concomitant traumatic brain injury.\n* Patients unable to communicate.\n* Patients unwilling to complete the study requirements.\n* Patients currently taking organic cat-ion transporter 2 (OCT2) inhibitors, e.g. Cimetidine.\n* Pregnancy, breastfeeding or incarcerated individuals.\n* Non-English speaking\n* Patients unable or unwilling to take calibrated (with gauge) photographs of their wounds","ALL","18 Years",{"count":17,"type":18},200,"ESTIMATED","INTERVENTIONAL",[21],"PHASE2","Many patients suffer from traumatic burns and current treatments do not increase the regenerative potential of either skin grafts or the remaining uninjured skin. There is a need to develop treatments to accelerate and improve healing of burn injuries. More research is needed to evaluate the role of 4-AP, a promising new agent with an excellent safety profile, on wound and burn healing. The investigational treatment will be used to test the hypothesis that 4-AP accelerates burn healing in traumatically burned patients.",[24,25,26],"Burns","Second Degree Burn","Wounds and Injuries",[28,29,24,30,31],"4-aminopyridine","4-AP","Second degree burn","Wounds","RECRUITING","2026-03-04",{"date":35,"type":36},"2026-03-05","ACTUAL",{"date":38,"type":36},"2026-01-01",{"date":40,"type":18},"2028-09",{"name":42,"class":43},"John Elfar","OTHER",1,{"id":46,"slug":4,"hasResults":10,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":19,"phases":55,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":4},"100538744","NCT06294821","4AP for Carpal Tunnel Syndrome (CTS)","4-Aminopyridine to Delay Carpal Tunnel Release or Resolve Carpal Tunnel Syndrome","CTS","Inclusion Criteria:\n\n* Patients diagnosed with non-traumatic carpal tunnel syndrome without any other confounding diagnosis (e.g. cubital tunnel syndrome, cervical nerve compression)\n* Standard of care EDX testing within 6 months of study enrollment\n* Cognitive ability to report sensory and motor deficit during examination.\n* Able to complete twice daily dosing of 4-AP for the entire 6 week treatment period.\n* Adults subject aged 18-90\n* Ability to give written informed consent.\n* Capable of safely undergoing electrodiagnostic testing (EDX).\n* Availability for all study visits.\n\nExclusion Criteria:\n\n* Inability to complete twice daily dosing during 6 week treatment period.\n* History of multiple sclerosis, stroke or any other diagnosed neurological disorder\n* History of hypersensitivity to AMPYRA® or 4-aminopyridine\n* Current use of aminopyridine medications, including other compounded 4-AP\n* Suspected renal impairment based on the Choyke questionnaire.","90 Years",{"count":54,"type":18},160,[21],"The investigators have found recent promising data supporting the use of a currently FDA approved drug, 4-aminopyridine, in the treatment of nerve injury including compression neuropathy. The purpose of this research is determine whether 4-aminopyridine can treat carpal tunnel syndrome or delay the need for formal surgical release in patients with known carpal tunnel syndrome who would otherwise undergo surgery.",[58,59],"Compression Neuropathy","Carpal Tunnel Syndrome",[61,62,63,64,50,65,66],"4 aminopyridine","carpal tunnel syndrome","CTR","4AP","Carpal tunnel release","compression neuropathy","NOT_YET_RECRUITING","2026-01-22",{"date":70,"type":36},"2026-01-26",{"date":72,"type":18},"2026-11",{"date":74,"type":18},"2028-07",{"name":42,"class":43},{"id":77,"slug":4,"hasResults":10,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":10,"sex":82,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":19,"phases":87,"briefSummary":89,"conditions":90,"keywords":93,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},"100339597","NCT03701581","4-aminopyridine Treatment for Nerve Injury","4-aminopyridine Treatment for Nerve Injury Resulting From Radical Retro-Pubic Prostatectomy","Inclusion Criteria\n\n* Male patients with organ-confined, non-metastatic prostate cancer (stages cT1c-T2c), planning to undergo Robotic-Assisted Laparoscopic Bilateral Nerve Sparing Radical Prostatectomy (NSRP)\n* Prostate-Specific Antigen (PSA) levels less than 15 ng\u002Fml (within the last 12 months), with biopsy-proven prostate cancer, for whom postoperative adjuvant therapy (e.g. radiation or androgen deprivation therapy) is not expected to be needed\n* Ages 45-75\n* An Abridged International Index of Erectile Function-Erectile Function (IIEF-5) score of greater than or equal to 17 at time of screening\n* Has experienced at least 6 months of regular sexual activity and sexual activity during the 12 weeks prior to prostate biopsy or surgery\n* Willingness to abstain from treatments for Erectile Dysfunction until 3 months after surgery\n* Willingness to participate and able to provide informed consent\n\nExclusion Criteria\n\n* Planned adjuvant therapy after NSRP based on specimen pathology and stage of prostate cancer (stage T3 or greater), positive lymph nodes or positive surgical margins\n* Neo-adjuvant therapy prior to NSRP\n* History of recurrent prostate cancer\n* History of seizures, multiple sclerosis, stroke or any other diagnosed neurological disorder\n* History of non-organ confined or metastatic prostate cancer (clinical Stages T3 or greater)\n* History of known hypersensitivity to 4AP\n* Patients with history of penile surgery other than circumcision or endoscopic urethral stricture surgery\n* Renal impairment based on calculated GFR (GFR\\\u003C60 mL\u002Fmin)\n* Use of any other aminopyridine medications for any other indication","MALE","45 Years","75 Years",{"count":86,"type":18},70,[21,88],"PHASE3","To evaluate the role of 4-aminopyridine (4-AP) on the course of recovery after peripheral nerve traction and\u002For crush injury. This study aims to test the hypothesis that 4-aminopyridine speeds the often slow and unpredictable recovery after peripheral nerve traction and\u002For crush injuries.",[91,92],"Nerve Injury","Prostate Cancer",[94,95,96,97,98],"prostatectomy","erectile dysfunction","prostate cancer","nerve injury","incontinence","2025-12-15",{"date":101,"type":36},"2025-12-17",{"date":103,"type":36},"2021-06-05",{"date":105,"type":18},"2028-12",{"name":42,"class":43},2,{"id":109,"slug":4,"hasResults":10,"nctId":110,"briefTitle":111,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":113,"sex":14,"minAge":15,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":19,"phases":117,"briefSummary":118,"conditions":119,"keywords":122,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":44},"100541692","NCT06333171","4-aminopyridine for Skin Wound Healing","Inclusion Criteria:\n\n* Otherwise healthy adult patients without skin conditions effecting the skin of the axilla or upper inner arm.\n* Cognitive ability to evaluate wound healing, report sensory and motor deficit during examination.\n* Eligible for standard of care plan for wound closure by secondary intention (normal healing without intervention).\n* Adults subject aged 18-70\n* Ability to give written informed consent.\n* Capable of safely coming in for follow up visits on all scheduled appointments.\n\nExclusion Criteria:\n\n* History of multiple sclerosis, stroke or any other diagnosed neurological disorder\n* History of hypersensitivity to AMPYRA® or 4-aminopyridine\n* Current use of aminopyridine medications, including other compounded 4-AP\n* Suspected renal impairment based on the Choyke questionnaire.\n* History of difficult compliance with timely follow up\n* Patients outside the age range\n* Unable to provide informed consent.\n* Patients with a known history of a seizure disorder (4-AP overdose can, in selected cases, result in limited seizure activity).\n* Patients with a concomitant traumatic brain injury.\n* Patients unable to communicate.\n* Patients unwilling to complete the study requirements.\n* Patients currently taking organic cat-ion transporter 2 (OCT2) inhibitors, e.g. Cimetidine.\n* Pregnancy, breastfeeding or incarcerated individuals.\n* Non-English speaking\n* Patients unable or unwilling to take calibrated (with gauge) photographs of their wounds",true,"70 Years",{"count":116,"type":18},150,[21],"Many patients suffer from chronic non-healing wounds as well as acute wounds. There is a need to develop treatments to accelerate and improve healing of chronic and acute wounds. More research is needed to evaluate the role of 4-aminopyridine (4-AP), a promising new agent with an excellent safety profile, on wound healing. The investigational treatment will be used to evaluate the role of (4-AP) on the treatment of wounds to accelerate wound healing in healthy adults.\n\nThe purpose of this study is to evaluate the role of 4-AP on the treatment of wounds to accelerate healing.\n\nThe investigational treatment will be used to test the hypothesis that 4-AP can speed wound healing.",[31,120,121,26],"Wound of Skin","Wound Heal",[61,123],"wound healing","2025-09-01",{"date":126,"type":36},"2025-09-03",{"date":128,"type":18},"2025-09",{"date":130,"type":18},"2028-03",{"name":42,"class":43},""]